Adverse Effects of Allergen Immunotherapy and Their Management
Allergen immunotherapy can cause both local and systemic reactions, with systemic reactions (including anaphylaxis) occurring in approximately 0.66% of injections, but severe life-threatening reactions are rare at approximately 1 in 1 million injections. 1, 2, 3
Types of Adverse Reactions
Local Reactions
- Manifest as redness, itching, and swelling at the injection site
- Manage with cool compresses, topical corticosteroids, or oral antihistamines 1
- Do not require treatment modification
Systemic Reactions
Systemic reactions range from mild rhinitis symptoms to life-threatening anaphylaxis 4. Most serious systemic reactions develop within 30 minutes after injection, though delayed reactions beyond 30 minutes can occur 1.
Critical Risk Factors to Assess Before Each Injection
You must evaluate these specific factors before every injection:
- Asthma control status - uncontrolled asthma is the most significant risk factor 1, 5, 6
- Measure peak expiratory flow rate; withhold injection if low for that patient 1
- Current allergen exposure (e.g., during pollen season) - increases reaction risk 5, 6
- Recent dose escalation or vial changes 5
- Beta-blocker use - associated with more severe reactions 6
- Girls and moderate asthmatics have higher systemic reaction rates 3
Patients with acute asthma exacerbations must have immunotherapy withheld 1.
Monitoring Protocol
Mandatory 30-minute observation period after every injection in a facility equipped to manage anaphylaxis 1. This is non-negotiable, as most serious reactions occur during this window, though you must counsel patients that delayed reactions can occur 1.
The facility must have:
- Trained staff capable of recognizing and treating anaphylaxis
- Immediate access to epinephrine and resuscitation equipment 1
Treatment of Systemic Reactions
Epinephrine is the first-line and only evidence-based treatment for anaphylaxis - administer immediately without delay 7, 8. This is the single most important intervention affecting morbidity and mortality.
Secondary medications (antihistamines and corticosteroids) should never replace epinephrine but may be used as adjuncts after epinephrine administration 1, 7. Note that routine corticosteroid use is no longer recommended in updated guidelines 9.
Severe cases may require:
- Intravenous saline
- Supplemental oxygen 1
Post-Reaction Management Algorithm
After any systemic reaction, follow this sequence:
- Re-evaluate the risk/benefit ratio of continuing immunotherapy 1
- Reduce the maintenance dose for some patients 1
- Adjust the immunotherapy schedule based on reaction severity 1
- Consider whether accelerated schedules (rush/cluster) contributed - these carry higher systemic reaction risk 1
Predictive Laboratory Markers
Higher blood eosinophil counts, basophil counts, and larger skin prick test diameters correlate with increased systemic reaction risk 3. While not absolute contraindications, these findings warrant heightened vigilance.
Common Pitfalls to Avoid
- Dosing errors and patient misidentification - the "human factor" is a major preventable cause of severe reactions 5
- Administering injections during uncontrolled asthma 1, 6
- Dose escalation during peak allergen season 5, 6
- Delaying epinephrine administration while attempting other treatments 7, 8
- Inadequate observation time after injection 1
Ongoing Surveillance
Schedule follow-up visits every 6-12 months to reassess:
- Symptom control and medication use
- Clinical response to immunotherapy
- Reaction history and compliance
- Need for schedule or dose adjustments 1
Important Context on Safety
Subcutaneous immunotherapy (SCIT) carries a small but real anaphylaxis risk, while sublingual immunotherapy (SLIT) has no reported fatalities 2. The rate of World Allergy Organization grade 4 (most severe) systemic reactions is approximately 1 in 1 million injections 2. With proper risk assessment, monitoring protocols, and immediate epinephrine availability, severe outcomes are preventable 5, 8.